Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Hits Expectations

Posted by George Bondi on May 13th, 2026

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32), Zacks reports. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%.

Tango Therapeutics Stock Performance

NASDAQ:TNGX traded up $2.01 on Wednesday, hitting $25.51. The stock had a trading volume of 3,298,683 shares, compared to its average volume of 3,243,074. The stock has a market cap of $3.68 billion, a P/E ratio of -29.32 and a beta of 1.22. Tango Therapeutics has a 1 year low of $1.25 and a 1 year high of $28.41. The firm’s fifty day simple moving average is $20.86 and its two-hundred day simple moving average is $13.95.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. HC Wainwright upped their target price on shares of Tango Therapeutics from $13.00 to $27.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Citigroup restated a “buy” rating on shares of Tango Therapeutics in a report on Monday, April 27th. Canaccord Genuity Group assumed coverage on shares of Tango Therapeutics in a report on Thursday, April 2nd. They issued a “buy” rating and a $30.00 target price on the stock. B. Riley Financial restated a “buy” rating on shares of Tango Therapeutics in a report on Friday, March 27th. Finally, Mizuho upped their target price on shares of Tango Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, March 11th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.44.

View Our Latest Report on Tango Therapeutics

Insider Buying and Selling

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $21.23, for a total value of $573,210.00. Following the completion of the sale, the insider owned 115,743 shares in the company, valued at approximately $2,457,223.89. This trade represents a 18.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 179,056 shares of company stock valued at $3,346,181. Company insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. Dynamic Technology Lab Private Ltd increased its stake in Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after buying an additional 15,037 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in Tango Therapeutics in the 4th quarter valued at about $35,000. Legal & General Group Plc increased its stake in Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after buying an additional 1,640 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Tango Therapeutics by 44.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $49,000 after acquiring an additional 2,907 shares during the period. Finally, Northeast Financial Consultants Inc bought a new position in shares of Tango Therapeutics during the 2nd quarter valued at approximately $51,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.